RATIONALE: Low blood levels of 25-hydroxyvitamin D (25[OH]D) have been associated with a higher risk of respiratory infections in general populations and higher risk of exacerbations of lung disease in people with asthma. We hypothesized that low blood levels of 25(OH)D in patients with chronic obstructive pulmonary disease (COPD) would be associated with an increased risk of acute exacerbations of COPD (AECOPD). OBJECTIVES: To determine if baseline 25(OH)D levels relate to subsequent AECOPD in a cohort of patients at high risk for AECOPD. METHODS:Plasma 25(OH)D was measured at baseline in 973 participants on entry to a 1-year study designed to determine if daily azithromycin decreased the incidence of AECOPD. Relationships between baseline 25(OH)D and AECOPD over 1 year were analyzed with time to first AECOPD as the primary outcome and exacerbation rate as the secondary outcome. MEASUREMENTS AND MAIN RESULTS: In this largely white (85%) sample of North American patients with severe COPD (mean FEV(1) 1.12L; 40% of predicted), mean 25(OH)D was 25.7 ± 12.8 ng/ml. A total of 33.1% of participants were vitamin D insufficient (≥20 ng/ml but <30 ng/ml); 32% were vitamin D deficient (<20 ng/ml); and 8.4% had severe vitamin D deficiency (<10 ng/ml). Baseline 25(OH)D levels had no relationship to time to first AECOPD or AECOPD rates. CONCLUSIONS: In patients with severe COPD, baseline 25(OH)D levels are not predictive of subsequent AECOPD. Clinical trial registered with www.clinicaltrials.gov (NCT00119860).
RCT Entities:
RATIONALE: Low blood levels of 25-hydroxyvitamin D (25[OH]D) have been associated with a higher risk of respiratory infections in general populations and higher risk of exacerbations of lung disease in people with asthma. We hypothesized that low blood levels of 25(OH)D in patients with chronic obstructive pulmonary disease (COPD) would be associated with an increased risk of acute exacerbations of COPD (AECOPD). OBJECTIVES: To determine if baseline 25(OH)D levels relate to subsequent AECOPD in a cohort of patients at high risk for AECOPD. METHODS: Plasma 25(OH)D was measured at baseline in 973 participants on entry to a 1-year study designed to determine if daily azithromycin decreased the incidence of AECOPD. Relationships between baseline 25(OH)D and AECOPD over 1 year were analyzed with time to first AECOPD as the primary outcome and exacerbation rate as the secondary outcome. MEASUREMENTS AND MAIN RESULTS: In this largely white (85%) sample of North American patients with severe COPD (mean FEV(1) 1.12L; 40% of predicted), mean 25(OH)D was 25.7 ± 12.8 ng/ml. A total of 33.1% of participants were vitamin D insufficient (≥20 ng/ml but <30 ng/ml); 32% were vitamin D deficient (<20 ng/ml); and 8.4% had severe vitamin D deficiency (<10 ng/ml). Baseline 25(OH)D levels had no relationship to time to first AECOPD or AECOPD rates. CONCLUSIONS: In patients with severe COPD, baseline 25(OH)D levels are not predictive of subsequent AECOPD. Clinical trial registered with www.clinicaltrials.gov (NCT00119860).
Authors: Sundari N Ampikaipakan; David A Hughes; Jackie C Hughes; Talar Amen; Graham Bentham; Andrew M Wilson Journal: Thorax Date: 2010-06-26 Impact factor: 9.139
Authors: F Andersson; S Borg; S A Jansson; A C Jonsson; A Ericsson; C Prütz; E Rönmark; B Lundbäck Journal: Respir Med Date: 2002-09 Impact factor: 3.415
Authors: Richard K Albert; John Connett; William C Bailey; Richard Casaburi; J Allen D Cooper; Gerard J Criner; Jeffrey L Curtis; Mark T Dransfield; Meilan K Han; Stephen C Lazarus; Barry Make; Nathaniel Marchetti; Fernando J Martinez; Nancy E Madinger; Charlene McEvoy; Dennis E Niewoehner; Janos Porsasz; Connie S Price; John Reilly; Paul D Scanlon; Frank C Sciurba; Steven M Scharf; George R Washko; Prescott G Woodruff; Nicholas R Anthonisen Journal: N Engl J Med Date: 2011-08-25 Impact factor: 91.245
Authors: M C Ockè; J Schrijver; G L Obermann-de Boer; B P Bloemberg; G R Haenen; D Kromhout Journal: J Clin Epidemiol Date: 1995-08 Impact factor: 6.437
Authors: Tian-Tian Wang; Frederick P Nestel; Véronique Bourdeau; Yoshihiko Nagai; Qiuyu Wang; Jie Liao; Luz Tavera-Mendoza; Roberto Lin; John W Hanrahan; Sylvie Mader; John H White; John H Hanrahan Journal: J Immunol Date: 2004-09-01 Impact factor: 5.422
Authors: Jennifer K Quint; Gavin C Donaldson; Nancy Wassef; John R Hurst; Michael Thomas; Jadwiga A Wedzicha Journal: BMC Pulm Med Date: 2012-06-22 Impact factor: 3.317
Authors: Louise Jeanette Pauline Persson; Marianne Aanerud; Pieter Sicco Hiemstra; Jon Andrew Hardie; Per Sigvald Bakke; Tomas Mikal Lind Eagan Journal: PLoS One Date: 2012-06-21 Impact factor: 3.240
Authors: Dennis Back Holmgaard; Lone Hagens Mygind; Ingrid Louise Titlestad; Hanne Madsen; Palle Bach Nielsen Fruekilde; Svend Stenvang Pedersen; C Pedersen Journal: PLoS One Date: 2013-01-14 Impact factor: 3.240